BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications

Journal of the Chinese Medical Association

Volumn 73, Issue 3, 2010, Pages 113-128

  Tang, Kam Tsun ^a,c   Lee, Chen Hsen ^b,c  

^a Department of Medical Education and Research ^*  (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

BRAF mutation; fine needle aspiration cytology; papillary thyroid cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AAL 881; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; B RAF KINASE INHIBITOR; BAY 43 6009; ISOQUINOLONE DERIVATIVE; LBT 613; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PHOSPHOTRANSFERASE INHIBITOR; PLX 4032; SORAFENIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANAPLASTIC CARCINOMA; ASPIRATION BIOPSY; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; LUNG CANCER; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; NONHUMAN; PANCREAS CANCER; PREOPERATIVE EVALUATION; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, PAPILLARY; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 77951020685     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(10)70025-3     Document Type: Review

References (156)

1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER website, 2009. [Date accessed: December 15, 2009]
2. Hundahl S.A., Fleming I.D., Fremgen A.M., and Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83 (1998) 2638-2648
3. Dohan O., Baloch Z., Banrevi Z., Livolsi V., and Carrasco N. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86 (2001) 2697-2700
4. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 (1994) 418-428
5. Mazzaferri E.L., and Kloos R.T. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86 (2001) 1447-1463
6. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
7. Gottlieb J.A., and Hill C.S. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med 290 (1974) 193-197
8. Shimaoka K., Schoenfeld D.A., DeWys W.D., Creech R.H., and DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 (1985) 2155-2160
9. th edition TNM classification system in a retrospective analysis of 169 patients. Thyroid 14 (2004) 65-70
10. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
11. Loh K.C., Greenspan F.S., Gee L., Miller T.R., and Yeo P.P. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82 (1997) 3553-3562
12. Kitamura Y., Shimizu K., Nagahama M., Sugino K., Ozaki O., Mimura T., Ito K., et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84 (1999) 4043-4049
13. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., et al. Mutations of the BRAF gene in human cancer 417 (2002) 949-954
14. Garnett M.J., and Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 (2004) 313-319
15. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endoc Rev 28 (2007) 742-762
16. Puxeddu E., Durante C., Avenia N., Filetti S., and Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19 (2008) 138-145
17. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
18. Robinson M.J., and Cobb M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9 (1997) 180-186
19. MacCorkle R.A., and Tan T.H. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43 (2005) 451-461
20. Wittinghofer A., and Nassar N. How Ras-related proteins talk to their effectors. Trends Biochem Sci 21 (1996) 488-491
21. Hancock J.F. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 4 (2003) 373-384
22. Weber C.K., Slupsky J.R., Herrmann C., Schuler M., Rapp U.R., and Block C. Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes. Oncogene 19 (2000) 169-176
23. Avruch J., Khokhlatchev A., Kyriakis J.M., Luo Z., Tzivion G., Vavvas D., and Zhang X.F. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56 (2001) 127-155
24. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 3 (2003) 459-465
25. Chong H., Lee J., and Guan K.L. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20 (2001) 3716-3727
26. Zhang B.H., and Guan K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19 (2001) 5429-5439
27. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 (2000) 289-305
28. Morrison D.K., and Cutler R.E. The complexity of Raf-1 regulation. Curr Opin Cell Biol 9 (1997) 174-179
29. Leicht D.T., Balan V., Kaplun A., Singh-Gupta V., Kaplun L., Dobson M., and Tzivion G. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773 (2007) 1196-1212
30. Mason C.S., Springer C., Cooper R.G., Superti-Furga G., Marshall C.J., and Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18 (1999) 2137-2148
31. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 (2003) 25-40
32. Marais R., Light Y., Paterson H.F., Mason C.S., and Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272 (1997) 4378-4383
33. Peyssonnaux C., and Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93 (2001) 53-62
34. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., Franklin R.A., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
35. Hagemann C., and Rapp U.R. Isotype-specific functions of Raf kinases. Exp Cell Res 253 (1999) 34-46
36. Ravi R.K., Weber E., McMahon M., Williams J.R., Baylin S., Mal A., Harter M.L., et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101 (1998) 153-159
37. Zhu J., Woods D., McMahon M., and Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12 (1998) 2997-3007
38. Wellbrock C., Karasarides M., and Marais R. The raf proteins take centre stage. Nat Rev Mol Cell Biol 5 (2004) 875-885
39. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
40. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTCRAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 (2003) 1454-1457
41. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev 6 (2006) 292-306
42. Ciampi R., and Nikiforov Y.E. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148 (2007) 936-941
43. Santoro M., Melillo R.M., and Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155 (2006) 645-653
44. Knauf J.A., Kuroda H., Basu S., and Fagin J.A. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22 (2003) 4406-4412
45. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., Caiazzo F., et al. The RET/PTCRAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115 (2005) 1068-1081
46. Mitsutake N., Miyagishi M., Mitsutake S., Akeno N., Mesa Jr. C., Knauf J.A., Zhang L., et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147 (2006) 1014-1019
47. Jhiang S.M., Sagartz J.E., Tong Q., Parker-Thornburg J., Capen C.C., Cho J.Y., Xing S., et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 (1996) 375-378
48. Santoro M., Chiappetta G., Cerrato A., Salvatore D., Zhang L., Manzo G., Picone A., et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12 (1996) 1821-1826
49. Powell Jr. D.J., Russell J., Nibu K., Li G., Rhee E., Liao M., Goldstein M., et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58 (1998) 5523-5528
50. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., and Fagin J.A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57 (1997) 1690-1694
51. Suarez H.G., du Villard J.A., Caillou B., Schlumberger M., Tubiana M., Parmentier C., and Monier R. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2 (1988) 403-406
52. Namba H., Rubin S.A., and Fagin J.A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4 (1990) 1474-1479
53. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., and Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol 120 (2003) 71-77
54. Daum G., Eisenmann-Tappe I., Fries H.W., Troppmair J., and Rapp U.R. The ins and outs of Raf kinases. Trends Biochem Sci 19 (1994) 474-480
55. Kondo T., Nakazawa T., Murata S., Kurebayashi J., Ezzat S., Asa S.L., and Katoh R. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 38 (2007) 1810-1818
56. Trovisco V., Vieira de Castro I., Soares P., Máximo V., Silva P., Magalhães J., Abrosimov A., et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202 (2004) 247-251
57. Ciampi R., Knauf J.A., Kerler R., Gandhi M., Zhu Z., Nikiforova M.N., Rabes H.M., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115 (2005) 94-101
58. Moretti S., Macchiarulo A., De Falco V., Avenia N., Barbi F., Carta C., Cavaliere A., et al. Biochemical and molecular characterization of the novel BRAF (V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 25 (2006) 4235-4240
59. Hou P., Liu D., and Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6 (2007) 377-379
60. Oler G., Ebina K.N., Michaluart Jr. P., Kimura E.T., and Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 62 (2005) 509-511
61. Ugolini C., Giannini R., Lupi C., Salvatore G., Miccoli P., Proietti A., Elisei R., et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17 (2007) 381-388
62. Kim T.Y., Kim W.B., Song J.Y., Rhee Y.S., Gong G., Cho Y.M., Kim S.Y., et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63 (2005) 588-593
63. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., Materazzi G., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 4085-4090
64. Sedliarou I., Saenko V., Lantsov D., Rogounovitch T., Namba H., Abrosimov A., Lushnikov E., et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 25 (2004) 1729-1735
65. Trovisco V., Soares P., Preto A., de Castro I.V., Lima J., Castro P., Máximo V., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446 (2005) 589-595
66. Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Liao X.H., Refetoff S., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65 (2005) 4238-4245
67. Mesa Jr. C., Mirza M., Mitsutake N., Sartor M., Medvedovic M., Tomlinson C., Knauf J.A., et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66 (2006) 6521-6529
68. Ouyang B., Knauf J.A., Smith E.P., Zhang L., Ramsey T., Yusuff N., Batt D., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12 (2006) 1785-1793
69. Salvatore G., Falco V., Salerno P., Nappi T., Pepe S., Troncone G., Carlomagno F., et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12 (2006) 1623-1629
70. Liu D., Liu Z., Condouris S., and Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92 (2007) 2264-2271
71. Wang J., Knauf J.A., Basu S., Puxeddu E., Kuroda H., Santoro M., Fusco A., et al. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 17 (2003) 1425-1436
72. Giordano T.J., Kuick R., Thomas D.G., Misek D.E., Vinco M., Sanders D., Zhu Z., et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 (2005) 6646-6656
73. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signaling by dual specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
74. Kim H.J., and Bar-Sagi D. Modulation of signaling by Sprouty: a developing story. Nat Rev Mol Cell Biol 5 (2004) 441-450
75. Traverse S., Gomez N., Paterson H., Marshall C., and Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells: comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 288 (1992) 351-355
76. Amit I., Citri A., Shay T., Lu Y., Katz M., Zhang F., Tarcic G., et al. A module of negative feedback regulators defines growth factor signaling. Nat Genet 39 (2007) 503-512
77. Dougherty M.K., Müller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., Conrads T.P., et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17 (2005) 215-224
78. V600E BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 106 (2009) 4519-4524
79. Mitsutake N., Knauf J.A., Mitsutake S., Mesa Jr. C., Zhang L., and Fagin J.A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65 (2005) 2465-2473
80. Ricarte-Filho J.C., Ryder M., Chitale D.A., Rivera M., Heguy A., Ladanyi M., Janakiraman M., et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69 (2009) 4885-4893
81. Paes J.E., and Ringel M.D. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37 (2008) 375-387
82. Yamashita S., and Saenko V. Mechanisms of disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 3 (2007) 422-429
83. Dal Maso L., Bosetti C., La Vecchia C., and Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 20 (2009) 75-86
84. Ron E., Lubin J.H., Shore R.E., Mabuchi K., Modan B., Pottern L.M., Schneider A.B., et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141 (1995) 259-277
85. Moysich K.B., Menezes R.J., and Michalek A.M. Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol 3 (2002) 269-279
86. Nikiforova M.N., Ciampi R., Salvatore G., Santoro M., Gandhi M., Knauf J.A., Thomas G.A., et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209 (2004) 1-6
87. Lee J.H., Lee E.S., Kim Y.S., Won N.H., and Chae Y.S. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38 (2006) 201-204
88. Frasca F., Nucera C., Pellegriti G., Gangemi P., Attard M., Stella M., Loda M., et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15 (2008) 191-205
89. Guan H., Ji M., Bao R., Yu H., Wang Y., Hou P., Zhang Y., et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94 (2009) 1612-1617
90. Adeniran A.J., Zhu Z., Gandhi M., Steward D.L., Fidler J.P., Giordano T.J., Biddinger P.W., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30 (2006) 216-222
91. Fugazzola L., Puxeddu E., Avenia N., Romei C., Cirello V., Cavaliere A., Faviana P., et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13 (2006) 455-464
92. Kebebew E., Weng J., Bauer J., Ranvier G., Clark O.H., Duh Q.Y., Shibru D., et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246 (2007) 466-471
93. Kim K.H., Suh K.S., Kang D.W., and Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 55 (2005) 540-545
94. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 (2003) 5399-5404
95. Rodolico V., Cabibi D., Pizzolanti G., Richiusa P., Gebbia N., Martorana A., Russo A., et al. BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid ≤ 1 cm and their paired lymph node metastases. Cancer 110 (2007) 1218-1226
96. Powell N., Jeremiah S., Morishita M., Dudley E., Bethel J., Bogdanova T., Tronko M., et al. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 205 (2005) 558-564
97. Xu X., Quiros R.M., Gattuso P., Ain K.B., and Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63 (2003) 4561-4567
98. Kim T.Y., Kim W.B., Rhee Y.S., Song J.Y., Kim J.M., Gong G., Lee S., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65 (2006) 364-368
99. Oler G., and Cerutti J.M. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115 (2009) 972-980
100. Elisei R., Ugolini C., Viola D., Lupi C., Biagini A., Giannini R., Romei C., et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93 (2008) 3943-3949
101. Jo Y.S., Li S., Song J.H., Kwon K.H., Lee J.C., Rha S.Y., Lee H.J., et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91 (2006) 3667-3670
102. Riesco-Eizaguirre G., Gutierrez-Martinez P., Garcia-Cabezas M.A., Nistal M., and Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 13 (2006) 257-269
103. Giannini R., Ugolini C., Lupi C., Proietti A., Elisei R., Salvatore G., Berti P., et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 3511-3516
104. Frattini M., Ferrario C., Bressan P., Balestra D., De Cecco L., Mondellini P., Bongarzone I., et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 (2007) 7436-7440
105. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88 (2003) 4393-4397
106. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., Carson K.A., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 6373-6379
107. Vasko V., Hu S., Wu G., Xing J.C., Larin A., Savchenko V., Trink B., et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90 (2005) 5265-5269
108. Trovisco V., Couto J.P., Cameselle-Teijeiro J., de Castro I.V., Fonseca E., Soares P., and Sobrinho-Simões M. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 69 (2008) 683-685
109. Lee J., Lee E.S., and Kim Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110 (2007) 38-46
110. Henderson Y.C., Shellenberger T.D., Williams M.D., El-Naggar A.K., Fredrick M.J., Cieply K.M., and Clayman G.L. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15 (2009) 485-491
111. Ito Y., Yoshida H., Maruo R., Morita S., Takano T., Hirokawa M., Yabuta T., et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56 (2009) 89-97
112. Abrosimov A., Saenko V., Rogounovitch T., Namba H., Lushnikov E., Mitsutake N., and Yamashita S. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 120 (2007) 196-200
113. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., Barbi F., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92 (2007) 2840-2843
114. Liu R.T., Chen Y.J., Chou F.F., Li C.L., Wu W.L., Tsai P.C., Huang C.C., et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63 (2005) 461-466
115. Mitsiades C.S., Negri J., McMullan C., McMillin D.W., Sozopoulos E., Fanourakis G., Voutsinas G., et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 6 (2007) 1070-1078
116. Park S.Y., Park Y.J., Lee Y.J., Lee H.S., Choi S.H., Choe G., Jang H.C., et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107 (2006) 1831-1838
117. Puxeddu E., Moretti S., Elisei R., Romei C., Pascucci R., Martinelli M., Marino C., et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89 (2004) 2414-2420
118. Sapio M.R., Posca D., Troncone G., Pettinato G., Palombini L., Rossi G., Fenzi G., et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154 (2006) 341-348
119. Romei C., Ciampi R., Faviana P., Agate L., Molinaro E., Bottici V., Basolo F., et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15 (2008) 511-520
120. Mian C., Barollo S., Pennelli G., Pavan N., Rugge M., Pelizzo M.R., Mazzarotto R., et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no (131)I uptake. Clin Endocrinol (Oxf) 68 (2008) 108-116
121. Di Cristofaro J., Silvy M., Lanteaume A., Marcy M., Carayon P., and De Micco C. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocr Relat Cancer 13 (2006) 485-495
122. Liu D., Hu S., Hou P., Jiang D., Condouris S., and Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 13 (2007) 1341-1349
123. Ikuyama S., Niller H.H., Shimura H., Akamizu T., and Kohn L.D. Characterization of the 5′-flanking region of the rat thyrotropin receptor gene. Mol Endocrinol 6 (1992) 793-804
124. Yokomori N., Tawata M., Saito T., Shimura H., and Onaya T. Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein. Mol Endocrinol 12 (1998) 1241-1249
125. American Association of Clinical Endocrinologists and Associazione MediciEndocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 12 (2006) 63-102
126. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., and Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur Endocrinol 154 (2006) 787-803
127. Leenhardt L., Grosclaude P., Chérié-Challine L., and Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee. Thyroid 14 (2004) 1056-1060
128. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 (2006) 2164-2167
129. Burgess J.R., Dwyer T., McArdle K., Tucker P., and Shugg D. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab 85 (2000) 1513-1517
130. Chow S.M., Law S.C., Au S.K., Mang O., Yau S., Yuen K.T., and Lau W.H. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. Clin Oncol 15 (2003) 329-336
131. Roti E., degli Uberti E.C., Bondanelli M., and Braverman L.E. Thyroid papillary microcarcinoma: a descriptive and metaanalysis study. Eur J Endocrinol 159 (2008) 659-673
132. Cappelli C., Castellano M., Braga M., Gandossi E., Pirola I., De Martino E., Agosti B., et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 95 (2007) 555-560
133. Baudin E., Travagli J.P., Ropers J., Mancusi F., Bruno-Bossio G., Caillou B., Cailleux A.F., et al. Microcarcinoma of the thyroid gland: the Gustave Roussy Institute experience. Cancer 83 (1998) 553-559
134. Roti E., Rossi R., Trasforini G., Bertelli F., Ambrosio M.R., Busutti L., Pearce E.N., et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 91 (2006) 2171-2178
135. Chan B.K., Desser T.S., McDougall I.R., Weigel R.J., and Jeffrey Jr. R.B. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 22 (2003) 1083-1090
136. Park Y.J., Kim Y.A., Lee Y.J., Kim S.H., Park S.Y., Kim K.W., Chung J.K., et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clinicopathological features, and immunohistochemical findings. Head Neck 32 (2010) 38-45
137. Lee X., Gao M., Ji Y., Yu Y., Feng Y., Li Y., Zhang Y., et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16 (2009) 240-245
138. Lee T.I., Yang H.J., Lin S.Y., Lee M.T., Lin H.D., Braverman L.E., and Tang K.T. The accuracy of fine-needle aspiration biopsy and frozen section in patients with thyroid cancer. Thyroid 12 (2002) 619-626
139. Salvatore G., Giannini R., Faviana P., Caleo A., Migliaccio I., Fagin J.A., Nikiforov Y.E., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 5175-5180
140. Cohen Y., Rosenbaum E., Clark D.P., Zeiger M.A., Umbricht C.B., Tufano R.P., Sidransky D., et al. Mutational analysis of BRAF in fine-needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10 (2004) 2761-2765
141. Marchetti I., Lessi F., Mazzanti C.M., Bertacca G., Elisei R., Di Coscio G., Pinchera A., et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 19 (2009) 837-842
142. Zatelli M.C., Trasforini G., Leoni S., Frigato G., Buratto M., Tagliati F., Rossi R., et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 161 (2009) 467-473
143. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., Haugen B.R., Klopper J.P., Zhu Z., Fagin J.A., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94 (2009) 2092-2098
144. Xing M., Clark D., Guan H., Ji M., Dackiw A., Carson K.A., Kim M., et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27 (2009) 2977-2982
145. Sala E., Mologni L., Truffa S., Gaetano C., Bollag G.E., and Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6 (2008) 751-759
146. Friday B.B., Yu C., Dy G.K., Smith P.D., Wang L., Thibodeau S.N., and Adjei A.A. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 68 (2008) 6145-6153
147. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
148. Liu D., Liu Z., Jiang D., Dackiw A.P., and Xing M. Inhibitory effects of the MEK inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 92 (2007) 4686-4695
149. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23 (2005) 5281-5293
150. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 (2004) 4456-4462
151. Kim S., Yazici Y.D., Calzada G., Wang Z.Y., Younes M.N., Jasser S.A., El-Naggar A.K., et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6 (2007) 1785-1792
152. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586
153. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S.J., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008) 4714-4719
154. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., Liang J., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27 (2009) 1675-1684
155. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., Licitra L., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359 (2008) 31-42
156. Cohen E.E., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., Kane M.A., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26 (2008) 4708-4713